In the incident and prevalent DD‐CKD trials, both vadadustat‐treated and darbepoetin‐treated patients maintained their serum EPO levels that were slightly increased at baseline compared with those of patients in the NDD‐CKD trials (20–32 mIU/mL) (Tables 1 and S2). The gene discussed is EPO; the disease is chronic kidney disease.